ClinicalTrials.gg
RecruitingNCT06965374FREELIFEUpdated May 13, 2026

Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson Disease

An observational study in Parkinson Disease, sponsored by AbbVie. Recruiting at 19 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by AbbVie · Observational

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
270
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Parkinson Disease by AbbVie — 5 open to participants now, 8 under way, none of them phase 3. Parkinson Disease · AbbVie.

Planned enrollment
5th of 18
270 · median 131
Started
2025
with 3 others
Observational
18 of 44
5 open now
Registered
40th of 44
by date

Among the 44 studies in Parkinson Disease by AbbVie, this one is the 5th largest by planned enrollment of the 18 observational ones that give a count, is one of 4 that started in 2025, is one of 18 observational ones, and was the 40th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

5 of the 44 studies in Parkinson Disease by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Parkinson Disease by AbbVie, or all of them as a file.
02

Study summary

Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective Foslevodopa/Foscarbidopa is in treating Italian adult participants with advanced Parkinson disease under routine clinical practice. This study will also assess the caregiver quality of life (QOL) (if caregiver is present).

Foslevodopa/Foscarbidopa is an approved drug for the treatment of Parkinson's Disease. Approximately 270 adult participants who are prescribed Foslevodopa/Foscarbidopa by their doctors will be enrolled across approximately 19 sites in Italy.

Participants will receive Foslevodopa/Foscarbidopa subcutaneous infusion as prescribed by their physician. Participants will be followed for up to 12 months.

There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Parkinson Disease
  • Foslevodopa/Foscarbidopa
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants with advanced Parkinson disease treated with Foslevodopa/Foscarbidopa according to label in Italy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a diagnosis of levodopa-responsive advance Parkinson's disease (PD)
  • Investigator decision on participant treatment with subcutaneous Foslevodopa/Foscarbidopa (LDp/CDp) made prior to, and independently, the decision to approach the participant to participate in the study
  • 24-h subcutaneous LDp/CDp treatment prescribed in accordance with the applicable approved label and local regulatory and reimbursement policies

Exclusion criteria

Exclusion Criteria:

  • Any condition included in the section of the approved local subcutaneous LDp/CDp label
  • Participation in a clinical trial of an drug, concurrently or within the last 30 days. Participation in another Post-Marketing Observational Study (PMOS) or Registry is acceptable
  • History of relevant skin conditions or disorders (e.g., psoriasis, atopic dermatitis) per investigator´s judgment. In case of temporary affections like recent sunburn, acne, scar tissue, tattoo, open wound, branding, or colorations, the subject should not be included if the investigator considers these as interfering with the infusion of study drug or with study assessments
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
270 participants (estimated)

Groups and cohorts

  • Foslevodopa/Foscarbidopa

    Participants will receive Foslevodopa/Foscarbidopa as prescribed by their physician according to local label.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Quality of Life as Measured by PD Questionnaire-39 (PDQ-39) Summary Index

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in PD. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The total score is between 0 and 156, calculated as the total sum of the items, and higher scores are associated with more severe symptoms. Negative changes from baseline indicate improvement.

    Time frame: Up to approximately 6 months

07

Study locations

19 of 19 sites recruiting
  • IRCCS Oasi SS. Troina /ID# 273507
    Troina, Enna 94018, Italy
    Recruiting
  • Istituto Neurologico Mediterraneo Neuromed S.P.A. - Irccs /Id# 272695
    Pozzilli, Isernia 86077, Italy
    Recruiting
  • ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO /ID# 272949
    Milan, Milano 20122, Italy
    Recruiting
  • Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 273225
    Milan, Milano 20133, Italy
    Recruiting
  • Azienda Ospedaliera Universitaria Luigi Vanvitelli /ID# 273434
    Naples, Napoli 80138, Italy
    Recruiting
  • A.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 273276
    Turin, Piedmont 10126, Italy
    Recruiting
  • Azienda Ospedaliera Universitaria Policlinico Tor Vergata /ID# 272834
    Rome, Roma 00133, Italy
    Recruiting
  • Azienda Ospedaliero-Universitaria Policlinico Umberto I /ID# 273562
    Rome, Roma 00161, Italy
    Recruiting
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Universita Cattolica /ID# 274539
    Rome, Roma 00168, Italy
    Recruiting
  • Azienda Ulss 3 Serenissima /ID# 273027
    Venice, Venezia 30100, Italy
    Recruiting
  • Azienda Ospedaliero Universitaria delle Marche /ID# 272694
    Ancona, 60020, Italy
    Recruiting
  • Ospedale Bellaria - Azienda Usl Di Bologna /ID# 274463
    Bologna, 40139, Italy
    Recruiting
  • IRCCS Centro Neurolesi Bonino Pulejo /ID# 273628
    Messina, 98124, Italy
    Recruiting
  • Azienda Ospedale-Universita Padova /ID# 274317
    Padova, 35128, Italy
    Recruiting
  • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone /ID# 272863
    Palermo, 90127, Italy
    Recruiting
  • Fondazione Mondino Istituto Neurologico Nazionale a Carattere Scientifico IRCCS /ID# 274226
    Pavia, 27100, Italy
    Recruiting
  • Azienda Ospedaliero Universitaria Pisana /ID# 273541
    Pisa, 56126, Italy
    Recruiting
  • AUSL di Reggio Emilia - Arcispedale Santa Maria Nuova /ID# 274388
    Reggio Emilia, 42122, Italy
    Recruiting
  • AOU San Giovanni di Dio Ruggi d'Aragona - Scuola Medica Salernitana /ID# 274319
    Salerno, 84131, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.

Of 60 industry-sponsored observational studies under Parkinson Disease, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's planned 24 months is below that.

Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2025
First posted
May 11, 2025
StartActual
Jun 4, 2025
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06965374
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
May 11, 2025
Start date
Jun 4, 2025
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
May 13, 2026

Study contacts

Caterina Golotta
Contact
caterina.golotta@abbvie.com
+39 06 548891
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion